
Opinion|Videos|August 8, 2024
Lower-Risk MDS: Frontline Therapy Initiation and Determination of Treatment Failure
Author(s)Mikkael Sekeres, MD
Dr Sekeres discusses when to start therapy for a patient who has lower-risk MDS with amnesia.
Advertisement
Clinical Presentation:
When do we start therapy for a patient who has lower-risk MDS with anemia?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































